IE883861L - Oral hygiene composition - Google Patents
Oral hygiene compositionInfo
- Publication number
- IE883861L IE883861L IE883861A IE386188A IE883861L IE 883861 L IE883861 L IE 883861L IE 883861 A IE883861 A IE 883861A IE 386188 A IE386188 A IE 386188A IE 883861 L IE883861 L IE 883861L
- Authority
- IE
- Ireland
- Prior art keywords
- oral hygiene
- same
- polymer
- hygiene composition
- chlorhexidine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 229920000642 polymer Polymers 0.000 claims abstract description 105
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 21
- 125000002091 cationic group Chemical group 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 90
- 229960003260 chlorhexidine Drugs 0.000 claims description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 19
- 125000004429 atom Chemical group 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- -1 rinse Substances 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 5
- 150000004287 bisbiguanides Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 239000008376 breath freshener Substances 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000000551 dentifrice Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000013010 irrigating solution Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 229940112822 chewing gum Drugs 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 abstract description 15
- 230000001580 bacterial effect Effects 0.000 abstract description 13
- 125000002843 carboxylic acid group Chemical group 0.000 abstract description 2
- 235000012041 food component Nutrition 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- 229920001281 polyalkylene Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 46
- 241001122767 Theaceae Species 0.000 description 24
- 230000002378 acidificating effect Effects 0.000 description 20
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 20
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 20
- 229920001223 polyethylene glycol Polymers 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 229920001817 Agar Polymers 0.000 description 10
- 239000008272 agar Substances 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000007598 dipping method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 5
- 229950010221 alexidine Drugs 0.000 description 5
- 230000000181 anti-adherent effect Effects 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229920001451 polypropylene glycol Polymers 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000004381 surface treatment Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 208000002064 Dental Plaque Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- 101710200114 Cysteine proteinase inhibitor 10 Proteins 0.000 description 2
- 101001003135 Homo sapiens Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 2
- 101001003132 Homo sapiens Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 2
- 101000633613 Homo sapiens Probable threonine protease PRSS50 Proteins 0.000 description 2
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- 102100029523 Probable threonine protease PRSS50 Human genes 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- SIHSSUWJKIEVGQ-UHFFFAOYSA-N 14-methyl-1-(14-methylpentadecoxy)pentadecane Chemical compound CC(C)CCCCCCCCCCCCCOCCCCCCCCCCCCCC(C)C SIHSSUWJKIEVGQ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100022907 Acrosin-binding protein Human genes 0.000 description 1
- 102100022498 Actin-like protein 8 Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 102100025215 CCN family member 5 Human genes 0.000 description 1
- 102100039635 Cancer/testis antigen 47A Human genes 0.000 description 1
- 102100031059 Cancer/testis antigen 55 Human genes 0.000 description 1
- 102100021439 Cancer/testis antigen 62 Human genes 0.000 description 1
- 101710117701 Cancer/testis antigen 62 Proteins 0.000 description 1
- 102100040901 Circadian clock protein PASD1 Human genes 0.000 description 1
- 102100032368 Coiled-coil domain-containing protein 110 Human genes 0.000 description 1
- 102100021967 Coiled-coil domain-containing protein 33 Human genes 0.000 description 1
- 102100027350 Cysteine-rich secretory protein 2 Human genes 0.000 description 1
- 102100031654 Cytochrome c oxidase subunit 6B2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000000253 Denture Cleanser Substances 0.000 description 1
- 102100037981 Dickkopf-like protein 1 Human genes 0.000 description 1
- 102100034323 Disintegrin and metalloproteinase domain-containing protein 2 Human genes 0.000 description 1
- 102100032484 Down syndrome critical region protein 8 Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102100038652 Ferritin heavy polypeptide-like 17 Human genes 0.000 description 1
- 102100027603 Fetal and adult testis-expressed transcript protein Human genes 0.000 description 1
- 102100020714 Fragile X mental retardation 1 neighbor protein Human genes 0.000 description 1
- 102100028673 HORMA domain-containing protein 1 Human genes 0.000 description 1
- 102100023042 Heat shock protein beta-9 Human genes 0.000 description 1
- 101000756551 Homo sapiens Acrosin-binding protein Proteins 0.000 description 1
- 101000678435 Homo sapiens Actin-like protein 8 Proteins 0.000 description 1
- 101000934220 Homo sapiens CCN family member 5 Proteins 0.000 description 1
- 101000746249 Homo sapiens Cancer/testis antigen 47A Proteins 0.000 description 1
- 101000922015 Homo sapiens Cancer/testis antigen 55 Proteins 0.000 description 1
- 101000613559 Homo sapiens Circadian clock protein PASD1 Proteins 0.000 description 1
- 101000868824 Homo sapiens Coiled-coil domain-containing protein 110 Proteins 0.000 description 1
- 101000897106 Homo sapiens Coiled-coil domain-containing protein 33 Proteins 0.000 description 1
- 101000726255 Homo sapiens Cysteine-rich secretory protein 2 Proteins 0.000 description 1
- 101000922370 Homo sapiens Cytochrome c oxidase subunit 6B2 Proteins 0.000 description 1
- 101000951345 Homo sapiens Dickkopf-like protein 1 Proteins 0.000 description 1
- 101000780288 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 2 Proteins 0.000 description 1
- 101001016533 Homo sapiens Down syndrome critical region protein 8 Proteins 0.000 description 1
- 101001031604 Homo sapiens Ferritin heavy polypeptide-like 17 Proteins 0.000 description 1
- 101000937113 Homo sapiens Fetal and adult testis-expressed transcript protein Proteins 0.000 description 1
- 101000932499 Homo sapiens Fragile X mental retardation 1 neighbor protein Proteins 0.000 description 1
- 101000985274 Homo sapiens HORMA domain-containing protein 1 Proteins 0.000 description 1
- 101001047330 Homo sapiens Heat shock protein beta-9 Proteins 0.000 description 1
- 101000705915 Homo sapiens Inactive serine protease 54 Proteins 0.000 description 1
- 101000971521 Homo sapiens Kinetochore scaffold 1 Proteins 0.000 description 1
- 101001130171 Homo sapiens L-lactate dehydrogenase C chain Proteins 0.000 description 1
- 101001054842 Homo sapiens Leucine zipper protein 4 Proteins 0.000 description 1
- 101001064302 Homo sapiens Lipase member I Proteins 0.000 description 1
- 101001088883 Homo sapiens Lysine-specific demethylase 5B Proteins 0.000 description 1
- 101001028659 Homo sapiens MORC family CW-type zinc finger protein 1 Proteins 0.000 description 1
- 101000825217 Homo sapiens Meiotic recombination protein SPO11 Proteins 0.000 description 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
- 101001128135 Homo sapiens NACHT, LRR and PYD domains-containing protein 4 Proteins 0.000 description 1
- 101000597425 Homo sapiens Nuclear RNA export factor 2 Proteins 0.000 description 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 description 1
- 101001100332 Homo sapiens Probable RNA-binding protein 46 Proteins 0.000 description 1
- 101000725916 Homo sapiens Putative tumor antigen NA88-A Proteins 0.000 description 1
- 101000679365 Homo sapiens Putative tyrosine-protein phosphatase TPTE Proteins 0.000 description 1
- 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 description 1
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 1
- 101000637373 Homo sapiens Sperm acrosome membrane-associated protein 3 Proteins 0.000 description 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 1
- 101000655622 Homo sapiens Testicular haploid expressed gene protein Proteins 0.000 description 1
- 101000596845 Homo sapiens Testis-expressed protein 15 Proteins 0.000 description 1
- 101000666379 Homo sapiens Transcription factor Dp family member 3 Proteins 0.000 description 1
- 101000674717 Homo sapiens Transcription initiation factor TFIID subunit 7-like Proteins 0.000 description 1
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 1
- 101000772169 Homo sapiens Tubby-related protein 2 Proteins 0.000 description 1
- 101000964582 Homo sapiens Zinc finger protein 165 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102100031071 Inactive serine protease 54 Human genes 0.000 description 1
- 102100021464 Kinetochore scaffold 1 Human genes 0.000 description 1
- 102100031357 L-lactate dehydrogenase C chain Human genes 0.000 description 1
- 102100026910 Leucine zipper protein 4 Human genes 0.000 description 1
- 102100030659 Lipase member I Human genes 0.000 description 1
- 102100033247 Lysine-specific demethylase 5B Human genes 0.000 description 1
- 102100037200 MORC family CW-type zinc finger protein 1 Human genes 0.000 description 1
- 102100022253 Meiotic recombination protein SPO11 Human genes 0.000 description 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
- 102100035403 Nuclear RNA export factor 2 Human genes 0.000 description 1
- AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 description 1
- 102100038818 Probable RNA-binding protein 46 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100027596 Putative tumor antigen NA88-A Human genes 0.000 description 1
- 102100022578 Putative tyrosine-protein phosphatase TPTE Human genes 0.000 description 1
- 102100021466 Sarcoma antigen 1 Human genes 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 102100021991 Solute carrier organic anion transporter family member 6A1 Human genes 0.000 description 1
- 102100032147 Sperm acrosome membrane-associated protein 3 Human genes 0.000 description 1
- 102100022441 Sperm surface protein Sp17 Human genes 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 102100032332 Testicular haploid expressed gene protein Human genes 0.000 description 1
- 102100035116 Testis-expressed protein 15 Human genes 0.000 description 1
- 102100038129 Transcription factor Dp family member 3 Human genes 0.000 description 1
- 102100021172 Transcription initiation factor TFIID subunit 7-like Human genes 0.000 description 1
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 1
- 102100029294 Tubby-related protein 2 Human genes 0.000 description 1
- 102100040814 Zinc finger protein 165 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000004808 allyl alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229920006321 anionic cellulose Polymers 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
An oral hygiene composition comprises effective amounts of a cationic anti-bacterial agent and a polymer which bears pendant polyalkylene side-chains and preferably carboxylic acid groups. Such compositions reduce both the bio-fouling of teeth and the staining thereof which may arise from the interaction of the cationic bacterial agent with dietary components.
[CA1335352C]
Description
This invention relates to oral hygiene compositions and to methods of using such compositions to prevent or inhibit growth of bacteria on tooth surfaces.
The prevention of the adherent deposition of dental plaque on mammalian (particularly human) teeth is a highly desired result. Dental plaque results when cariogenic and other types of bacteria aggregate in colonies on the surface of teeth and form a deposit which adheres tenaciously to the surface. It is believed that the deposition of plaque on the surface of a tooth is one of the first steps in-the development of dental caries and periodontal disease.
Many attempts have been made to prevent the deposition of plaque on tooth surfaces and to effect removal of plaque from such surfaces. For example, brushing, dental flossing and the use of oral irrigators and interdental stimulators have been tried. Such treatments are not, however, entirely successful and must often be supplemented with periodic treatment by dental professionals.
In our recently published European Patent Specification No 0,182,523A, we teach that certain pharmaceutical compositions (as therein defined) are highly effective for preventing or significantly reducing (a) the colonisation of tooth surfaces or simulated tooth surfaces by cariogenic and other microorganisms commonly found in an oral environment, and (b) the adherent deposition on tooth surfaces of dental plaque resulting from such microorganisms.
The preparation of polymers for use in the aforesaid certain pharmaceutical compositions is described in EP 0,182,523A.
Chlorhexidine is a cationic antiseptic which has been widely used by the medical profession as a topical antibacterial agent for more than 20 years; the preparation thereof is described in UK 705.838. It has been reported (Loe _et _&1, Journal of Periodontal Research, 1970. Vol 5, pp79-83) that chlorhexidine can be used as an antiseptic in the oral environment and that in certain circumstances there is a tendency apparently for chlorhexidine to stain teeth. Such staining appears to be a property which is common to cationic antiseptics. It has been shown (Addy et al_, Journal of Periodontal Research, volume 9, pp 134-140) that such staining is the result of an interaction between the cationic antiseptic and dietary components, particularly those rich in tannins, e.g. coffee, tea or red wine.
We have now found that where certain surfaces, e.g. tooth, or hydroxyapatite, are treated with a combination of both (a) a polymer, as hereinafter defined, which bears certain pendant polyalkylene oxide chains, and (b) a cationic antibacterial agent, the resulting treated tooth surfaces surprisingly exhibit both enhanced antiadhesive and antibacterial properties to certain oral micro-organisms, i.e. the combination may effect control of so-called "bio-fouling" of tooth surfaces.
Indeed, in the presence of the said polymer, equivalent antibacterial effects can be observed where the tooth surface is treated with a lower concentration of a solution of the antibacterial agent. Furthermore, we have now found, surprisingly, (i) that the aforesaid tendency for staining with chlorhexidine is at least reduced, there is often no increase in staining even where more chlorhexidine is adsorbed on the tooth surface in the presence-of the aforesaid polymer; (ii) the antibacterial properties of certain cationic 4 antibacterial*a9ents, e.g. chlorhexidine and alexidine, are increased on simulated tooth surfaces if the surface is treated sequentially with or with a combination of, an acidic polymer, e.g. Polymer 93W (as hereinafter 5 defined) and the aforesaid agent; and (iii) where composite restorations, e.g. Occlusion (RTM), Opalux , Silux and Valux P50, etc, tend to be stained by cationic antiseptics such staining is at least alleviated in the presence of the aforesaid polymer. It will be 10 appreciated that reduction at least of such staining of anterior teeth is particularly desirable.
According to the present invention there is provided an oral hygiene composition comprising (i) an effective amount of at least one cationic 15 antibacterial agent; and (ii) an effective amount of at least one polymer which bears pendant polyalkylene oxide side-chains.
As examples of cationic antibacterial agents which may be used in the present invention may be 20 mentioned inter alia benzalkonium chloride, bispyridinamines, e.g. octenidine, or preferably a poly-biguanide, e.g. alexidine, or more preferably a bis-biguanide, e.g. chlorhexidine.
By "polybiguanide" we mean a compound which has a 25 plurality of in-chain biguanide residues of the general formula I NH NH II II -NH-C-NH-C-NH- I or tautomers thereof. Often there are two, three or four such in-chain residues in the antibacterial agent used in 30 the present invention. However, we do not exclude the possibility that there may be sufficient to provide at least a major portion of the repeat units of a higher 5 molecular weight polymer, e.g of molecular weight up to about 10,000.
It will be appreciated that where a polybiguanide is used in the present invention it may be present as a 5 free base; preferably, however, it is present as a salt thereof, e.g. acetate or hydrochloride, or more preferably, particularly where the polybiguanide is a bis-biguanide which has the structure shown in general Formula II, as the di-gluconate, i.e. the di-gluconate 10 of 1, 6-di (4-chlorophenyl-diguanido)hexane, which is known in the art as chlorhexidine.
CI nh II nh y nh-c-nh-c-nh(chj) 6nh-c-nh-c-nh/ \ nh II NH CI II We do not exclude the possibility that where a polybiguanide, e.g. chlorhexidine, in the form of a free 15 base is used in the present invention it may be in admixture (e.g. as a salt) on the tooth surface as a salt with an acidic polymer as hereinafter defined.
As possible explanations, without wishing to be bound thereby, of the increased antibacterial effect of 20 the oral hygiene composition of the present invention, we suggest: (i) an increase in the quantity of chlorhexidine adsorbed on the tooth surface; and/or (ii) alteration in the strength of adsorption of 25 chlorhexidine at the tooth surface such that it is more available to exert its antibacterial effect at the surface; and/or (iii) alteration in the orientation at the tooth surface of adsorbed chlorhexidine such that the (i antibacterial groups thereof are more accessible to bacteria approaching thereto; and/or (iv) ion-pairing between the cationic antibacterial agent and the acid anions, where present, of the 5 polymer.
In the composition according to the present invention, multiple hydrogen-bonds between the polymer, and the biguanide cations may contribute to the aforesaid increase in quantity or alteration in strength of 10 adsorption or orientation.
Polymers of which the oral hygiene composition according to the present invention are comprised are preferrably acidic, by which we mean that there is at least one carboxylic acid group appended to the polymer 15 backbone. However, we do not exclude the possibility that the polymer may be amphoteric, basic or neutral, although this not preferred.
The one or more pendant polyalkylene oxide groups appended to the polymers of which oral hygiene 20 compositions according to the present invention are comprised are preferably ethylene oxide groups.
However, we do not exclude the possibility that at least a portion thereof may be alternative poly(lower)-alkylene oxide groups, e.g. polypropylene. 25 As examples of polymers of which the oral hygiene composition according to the present invention are comprised may be mentioned inter alia polymers which comprise one or more repeating units of general structure A and one or more repeating units of general structure B wherein X, which in the repeating units of structure A may be the same or different, and Y, which in the repeating units of structure B may be the same or different, are hydrocarbyl, or substituted hydrocarbyl residues, providing a backbone for the polymer; Z is -CHR1-CHRJ-or-(CHj)m*; wherein, where Z is -CHRX-CHR2", R1, which in the same repeating unit of structure B (when n or q is 2 or more) or in different repeating units of structure B may be the same or different, is hydrogen or a hydrocarbyl group: and RJ, which in the same repeating unit of structure B (when n or q is 2 or more) or in different repeating units of structure B may be the same or different, is, hydrogen or a hydrocarbyl group; except that Rl and R' in a single unit-CHR1-CHRa-0- cannot both be hydrocarbyl; y M r3, which in the same repeating unit of structure b (when q is 2 or more) or in different repeating units of structure b may be the same or different, is hydrogen or a hydrocarbyl group or an acyl group derived from an alkanoic acid having up to five carbon atoms; m, where present, is a number of from 2 to 10; n is a number of from 1 to 60; p is a number of from 1 to 4; and q is a number of from 1 to 4; each (COjH) group is joined via an intermediary or intermediaries L to the hydrocarbyl residue X, and in cases where p is 2 to 4 may be joined by L to the same or different carbon atoms of X; l may be the same or different In the repeating units of structure A and is selected from one or more direct links and one or more groups of atoms each group providing a chain of one or more atoms for linking a (COjH) group with X, except that more than two (COjH) groups cannot be directly linked to the same carbon atom in X; each ((Z0)nR3)q group is joined via an intermediary or intermediaries M to the hydrocarbyl residue Y, and in cases where q is 2 to 4 may be joined by M to the same or different carbon atoms of Y; M may be the same or different in the repeat units of structure B and is selected from one or more direct links and one or more groups of atoms each group providing a chain of one or more atoms for linking a (Z0)n group with Y, except that more than two (Z0)n groups cannot be directly linked to the same carbon atom in Y; the ratio of the number of -C0,H groups to the number of (ZO) groups, particularly where Z is -CHaCHa-. is within the range of 1:20 to 20:1 3 Preferably both Rl and RJ. where they are present, are hydrogen.
Where R1 or R* is a hydrocarbyl group, it is preferably a lower alkyl group, more preferably methyl.
RJ is preferably a lower alkyl group, more preferably methyl.
Where Z is -(CH2)m". m is preferably 4; this affords a ready preparation of-(ZO)n* from tetrahydrofuran.
It is to be understood that the definition of the polymer contained in the composition (as given above) is also intended to embrace a polymer in which at least some of the carboxyl groups in the repeat units of general structure A have been converted to the corresponding salt anions C02- (these being considered as -COjH group as far as the ratio of carboxyl to -Z0-groups is concerned), the corresponding cations for example being those of ammonium (NH+4), or alkaline earth metals or preferably alkali metals (e.g. Na+, K+). We do not exclude the possibility that the cation may be derived from the cationic antibacterial agent per se; indeed where the cationic antibacterial agent is present as a salt of the acid polymer such that there is substantially no free chlorhexidine in the mouth there is a tendency for staining to be further reduced.
In general structure A, each carboxyl group is joined to the hydrocarbyl residue X by means of an intermediary or intermediaries (i.e. by a linking entity or entities), this or these being denoted by L, which is selected from one or more direct links (i.e. one or more direct bonds) and one or more groups of atoms each group providing a chain of one or more atoms for linking a carboxyl group(s) with X. In cases where p is 2 to 4. each carboxyl group may be joined by L to the same or, in cases where L represents more than one intermediary, to w the same or different carbon atoms in X, although more than 2 carboxyl groups cannot of course be directly linked to .the same carbon atom of X (and also assuming that in such cases X has at least 2 carbon atoms, whereas 5 it should be appreciated that it is within the scope of the invention for X to have only 1 carbon atom) . It will be noted that in principle L can represent up to 4 separate intermediaries in structure A (in cases where p is 4). L may be the same or different in the repeat 10 units of structure A.
In cases where L represents one or more groups of atoms each group providing a linking chain of atoms, the chain will normally comprise one or more carbon atoms (which could, for example, include carbon atoms in an 15 aryl ring) and/or hetero atoms (particularly N and/or 0). Examples of possible linkages provided by L are: (direct link or bond) where (apart from the direct link) the top link is to X and the bottom link(s) is to carboxyl. It is preferred 20 in the present invention, however, that L is one or more direct links, such that each carboxyl group is joined directly to a carbon atom in the polymer backbone.
In the structure A, p is preferably 1 or 2, more preferably 1 (so that L can then represent one, or at 25 most, two intermediaries).
CH2 CH, CH, NH CO CO CH, CH CO NH / \ I I NH CH(CH,) CH(OH) 11 1 X In structure B, each (Z0)n R3 group is joined tc the hydrocarbyl residue Y by means of an intermediary or intermediaries (i.e. by a linking entity or entities), this or these being denoted by M, which is selected from 5 one or more direct links (i.e. one or more direct bonds) and one or more groups of atoms each group providing a chain of one or more atoms for linking a (Z0)n R3 group(s) with Y. In cases where q is 2 to 4, each (Z0)n R3 group may be joined by M to the same or. in 10 cases where M represents more than one intermediary, to the same or different carbon atoms in Y, although more than two (Z0)n R1 groups cannot of course be directly linked to the same carbon atom of Y (and also assuming that in such cases Y has at least 2 carbon atoms, whereas 15 it should be appreciated that it is within the scope of the invention for Y to have only 1 carbon atom) . M may be the same or different in the repeat units of structure B.
While M may represent one or more direct links, it 20 is preferred in the present invention that M is one or more groups of atoms each group providing a linking chain of atoms; such a chain will normally comprise one or more carbon atoms (which could, for example, include carbon atoms in an aryl ring, e.g. benzyl ether) and/or hetero 25 atoms (particularly N and/or 0) . Particularly preferred examples of chains provided by M are: CO and CO NH where the top link is to Y and the bottom link is to (ZO)n R3.
In structure B. q is preferably 1 or 2, more preferably l(so that M can then represent one. or at most two intermediaries).
Preferably the structure A represents the repeat unit derivable by the addition polymerisation (usually free-radical initiated) of a polymerisable olefinically unsaturated carboxylic acid. Examples of such acids are maleic (or fumaric) acid, itaconic acid, the acids of formulae C(CK3)=CH3 CH=CH2 I I CO and CO I I NHCH(CH,)COjH NHCH(OH)COaH N-methacryloyl alanine— N-acryloyl-hydroxy-glycine or preferably acrylic or methacrylic acid Preferably the structure B represents the repeat unit derived from the polymerisation (usually free-radical initiated) of an addition polymerisable olefinically unsaturated ester or amide formed from the reaction of an unsaturated carboxylic acid (or an esterifiable or amidifiable derivative thereof such as an acid chloride or anhydride) and a hydroxy compound of formula HO (Z0)n R» (to form the ester) or an amine of formula HaN (Z0)n R3 (to form the amide).
Preferably the acid from which structure B is derivable is acrylic or methacrylic acid, particularly the latter, giving rise, where an ester or amide derivative of methacrylic acid is used, to the following structures respectively for B: 13 -c(chj) ch, CO and CO 0 (zo)n r>.
NH (ZO)n Rs 10 15 20 Preferably acidic polymers of which oral hygiene compositions according to the present invention are comprised have a ratio of acidic residues to pendant polyalkylene oxide residues of about 6:1 (where each side chain is polyethylenegylcol of molecular weight about 350, i.e. so-called PEG 350).
Polymers for use in the present invention are more fully described in our aforesaid European Patent Specification No 0,182,523A.
In oral hygiene compositions of the present invention, the at least one polymer present therein is typically at least at a concentration of about 0.05 to 30 weight % of the composition, the preferred concentration range being from about 0.1 to 5 weight % and more preferably 0.2 to 2 weight %.
The concentration of the at least one antibacterial agent in oral hygiene compositions according to the present invention is about 0.001 to 10 weight % of the composition, the preferred concentration range being from about 0.001 to 1.0 weight % and more preferably 0.01 to 0.1 weight %. r- Preferably, the mass of the polymer is higher than the mass of the anti-bacterial agent in oral hygiene composition according to the present invention. However, we do not exclude the possibility that there may be more anti-bacterial agent than polymer present.
H The oral hygiene composition of the present invention typically comprises only one polymer as hereinbefore defined, although we do not exclude the possibility that two or more such polymers may be present 5 in the composition.
The skilled man by simple experiment will be able to formulate compositions according to the present invention in which the ratio of antibacterial agent to polymer is such that undesired reaction is avoided. 10 The oral hygiene composition of the present invention typically comprises a pharmaceutical^ acceptable vehicle which is compatible,with the antibacterial efficacy of the cationic antibacterial agent, e.g. chlorhexidine. To maintain the efficacy of 15 chlorhexidine it may be necessary to adjust the concentration thereof in a particular vehicle, a suitable concentration may be determined by the skilled man by experiment.
Suitable conventional pharmaceutical^ acceptable 20 vehicles that can be employed in the oral hygiene compositions of the present invention include water, ethanol (wherein water, or a water/ethanol mixture will often be a major component of the vehicle); such humectants as propylene Glycol, isopropanol, glycerol and 25 sorbitol; such gelling agents as cellulose derivatives, for example, hydroxypropyl and hydroxyethyl cellulose, polyoxypropylene/polyoxyethylene block copolymers, (so-called "Poloxamers"), for example Synperonic PE 39/70 and PEF 87; certain gel stabilisers such as 30 polyvinylpyrrolidone; sweeteners such as sodium saccharin; preservatives such as cetylpyridinium chloride, and certain lower alkyl parahydroxybenzoates; surfactants such as polyoxyethylene isohexadecyl ether (Arlasolve 200) and certain colours and flavours, on the approved EEC or FD&C lists. It will be appreciated that the aforesaid vehicle is chosen such that it does not unduly inhibit the effectiveness of the oral hygiene composition according to the present invention; in particular, an anionic material, eg an anionic cellulose derivative or an anionic Synperonic, is not preferred.
The oral hygiene compositions of the present invention may be in the form of any conventional pharmaceutically acceptable oral hygiene formulation that contains (and is compatible with) an effective amount of a polymer and antibacterial agent as hereinbefore defined. As examples of such formulations may be mentioned inter alia mouthwashes, rinses, irrigating solutions, abrasive and non-abrasive gel dentifrices, denture cleansers, coated dental floss, coated or impregnated toothbrush bristle (natural or synthetic), inter-dental stimulator coatings, chewing gums, lozenges, breath fresheners, foams and sprays.
The present invention is now illustrated by the following Examples. The prefix "CT" to an Example number denotes a Comparative Test.
In most of the following Examples the oral bacterium Streptococus mutans NCTC 10449 was used as the standard bacteria. It was grown in Brain Heart Infusion (BHI) (ex Oxoid) in a Bioflo Model C30 Fermenter. A 750 ml pot was used containing 350 ml of bacterial suspension. The bacteria were grown at 37 *C with a dilution rate of O.lh"1, an air flow of 0.24 litre/minute and an agitation speed of 300 rpm. A sample (approximately 20 ml) of bacterial suspension was taken out of the fermenter for each experiment. The bacteria were centrifuged for 10 minutes at 4000 rpm, they were resuspended in modified Ringer's salts solution (0.54 grams/litre NaCl; 0.02 grams/litre KC1; 0.03 grams/litre 15 CaCl,; and 0.75 grams/litre sodium mercaptoacetate) . recentrifuged, resuspended and diluted (10 x) in modified Ringer's salts solutions. The approximate bacterial concentration in the diluted salts solutions was 10* ml-1.
Streptococcus mltior NCTC 7 864 was grown in 100ml Brain Heat Infusion broth in batch culture for 24 hours. The culture was then centrifuged for 30 minutes at 3500rpm and washed twice by resuspending the pellet in saline and centrifuging. The bacterial suspension was then adjusted to approximately lO'-lO* cells per ml.
Whole saliva was used in further examples. Absorption surfaces Hydroxyapatite discs were made by compressing hydroxyapatite powder (calcium phosphate tribasic (Ca10 (OH), (P04), (ex Aldrich)) and sintering at 1100*C. The discs were re-used after heating in a furnace at 900#C for 2 hours between experiments.
Application of polymers Hydroxyapatite discs were treated for 2 minutes at room temperature with a solution (1% w/v) of a polymer, e.g. Polymer 93W, in a 1:1 (by volume) mixture of industrial methylated spirits/water. The discs were then washed by dipping and shaking 5 times in a container of flowing water at about 15°C.
Application of Anti-Bacterial Agent Aqueous solutions of chlorhexidine and IMS solutions of alexidine were separately adsorbed for certain periods of time onto the surfaces of hydroxyapatite discs which had been treated with polymer where appropriate (untreated discs were used in comparative tests). The discs were then washed by dipping and shaking 5 times into a container of flowing water.
A J Polymers The polymer herein referred to as "Polymer 93W" is an acidic polymer as described and prepared in Example 5 of our aforesaid EP.182523. (Other "acidic" polymers hereinafter described were prepared by a similar process). Polymer 93W comprises methacrylic acid and PEG350MAt residues in molar ratio 6: 1.
By "PEG350MAt" we mean a polyethylene oxide of. molecular weight about 350 which has been capped with methoxy and methacryloyl groups, i.e.
CH^CfCHjKOOfCHjCHjOJnCH,, where n is about 8.
PEG 150Mat. PEG1000 Mat and PEG 2000 Mat indicate similar polyethylene oxides of molecular weights 150, 1000 and 2000 respectively.
Polymer Mil was prepared under the conditions described in Example 15 of EP 182,523 except that a hydroxy ended PEG was used instead of an amino ended PEG. Loeffler's Methylene Blue 95% Ethyl alcohol (30 ml), methylene blue (0.3 g) and water (100 ml).
Examples 1-2 These Examples demonstrate that Polymer 93W retains its anti-adhesive properties in the presence of absorbed chlorhexidine.
Hydroxyapatite discs were treated with a 1% w/w solution of Polymer 93W and then with certain antibacterial agents for set periods of time. The discs so treated were immersed in a bacterial suspension (30 mis) in a petri-dish for 2 hours. The discs were removed from the bacterial suspension and were washed by dipping and shaking 5 times in a container of flowing water. Bacteria adhering to the discs were stained using Loeffler's Methylene Blue. The reduction in bacterial adhesion was determined by microscopic examination. 18 The results are shown in Table 1.
TABLE 1 Example No Antibacterial Agent Polymer % Anti-adhesion CT1 0 1%93 W 99 1 C 1%93 W 99 2 A 1%93 W 99 CT1: 1% 93W was used alone C: 1% chlorhexidine A : 1% alexidine From Table 1 it can be seen that chlorhexidine and alexidine do not reduce the anti- adhesive properties of Polymer 93W deposited on hydroxyapatite discs.
"%Anti-adhesion" ("% AA") is defined by the equation: %AA = Area of neat surfacel- ' Area of polymer- -coated j covered with bact. 1 surface covered with bactJ Area of neat surface \ I covered with bacterial It will be appreciated that (a) where the polymer does not decrease the area of the surface which is coated with bacteria then: % AA = X-X x 100 = 0 X and (b) where the polymer prevents adhesion of bacteria to the surface then: % AA = X-0 x 100 = 100 19 Similar results were obtained when a specimen of material conventionally used in the preparation of a dental prosthetic device, as hereinafter described, was treated with polymer 93W and chlorhexidine was then 5 exposed to Streptococcus mitior NCTC 7864.
EXAMPLES 3-5 These Examples demonstrate that on hydroxyapatite the antibacterial effect of chlorhexidine at certain concentrations is increased where it is used in the 10 presence of Polymer 93W.
Solutions of chlorhexidine were absorbed onto sterile hydroxyapatite discs which had been treated with Polymer 93W. Cells of S^_ mutans were taken from a fermenter and diluted 100 fold in BHI agar at 40°C. The 15 innoculated agar was overlayed onto KAP discs.
Agar coated discs were incubated at 37#C overnight. Bacterial growth throughout the agar was assessed on a scale of 0 (no growth) to 10 (control).
Since the surface of each hydroxyapatite disc was 20 brought into contact with the same number of bacteria in each case, anti-adhesion did not contribute to the observed result, i.e. antibacterial effect alone was being measured. The results in Table 2 reveal that the combination of Polymer 93W and chlorhexidine gave an 25 enhanced antibacterial effect compared to chlorhexidine per se at the same applied concentration of chlorhexidine.
In Comparative Tests CT's 2, 3, 4 and 5, the discs were not treated with Polymer 93W. Comparative Test 2 is 30 a blank; in Comparative Test 2A, the disc was treated with Polymer 93W only. 20 TABLE 2 Example Applied Treatment with Bacterial No Chlorhexidine concentration Polymer 93W growth CT2 0 NO 10 CT2A 0 YES 10 CT3 1 NO 8 CT4 0.1 NO 10 CT5 0.01 NO 10 3 1 YES 0 4 0.1 YES 2 5 0.01 YES 4 EXAMPLES 6-9 These Examples demonstrate the combination of anti-adhesive and antibacterial results which can be ootained from the use of a combination of a polymer and chlorhexidine and that such a combination provides an improvement over the discrete components per se.
Sterile hydroxyapatite discs were treated with a 1% w/v solution of Polymer 93W and then with solutions of certain-concentrations of chlorhexidine. The discs were incubated in freshly collected whole saliva for 1 hour at 37*c and washed by dipping and shaking 5 times into a container of flowing warsr. Excess water was removed from the surface of each disc by touching the edge thereof with filter paper.
BHI agar containing 0.04% w/v Bromo Cresol Green (to render bacterial growth on the white hydroxy-apatite discs visible) was pipetted at 40*C onto the discs such that a thin film of agar formed on the surface. 21 The discs were incubated at 37°C overnight. The results are shown in Table 3.
In Comparative Tests 6-10 the treatment with Polymer 93W was omitted. In Comparative Test 11, 5 Polymer 93W was used, in the absence of chlorohexidine. n TABLE 3 5 10 15 20 25 30 35 Example Concentration of Presence of Bacterial No chlorhexidine (%} Polymer 93W growth CT6 1 NO No Growth 6 1 YES No growth CT7 0.1 NO Control level 4. 7 0.1 YES No Growth CT8 o • o NO Control level 5. 0 O o H YES A few colonies: greater than 99% reduction compared with control level 5 CT9 0.001 NO Control level 6. 9 0.001 YES 99% reduction compared with control level 6 CT10 0 NO Thick Growth: control level 7 CT11 0 YES 90% Reduction compared with CT7 control level 7 From Table 3 it can be seen that for certain concentrations of chlorhexidine, e.g. 0.01 and 0.001%, the presence of Polymer 93W increases the bactericidal and/or bacteriostatic effect thereof. CT11 demonstrates the reduction in bacterial growth which arises from the anti-adhesion properties of the polymer per se.
EXAMPLES 10-20 These Examples reveal that treatment of hydroxyapatite discs with certain polymers (a) increases the amount of chlorhexidine absorbed thereon and (b) improves the retention of the absorbed chlorhexidine through subsequent wa'shing treatments.
Preparation of Polymers B3 and B18 Methacryloyl chloride (0.58 moles) was added over 2 hours to a mixture of toluene (600 ml), Jeff "360" or "2070" (0.5 moles) and 2,6-lutidine (0.56 moles) cooled in an ice-bath. A copious white precipitate formed. The reaction mixture was allowed to stand for 3 hours, and the white precipitate was filtered off and washed with toluene. The filtrate was evaporated under reduced pressure and the residue was kept under vacuum to remove volatiles. Products (yield 80-90%) were characterised by infra-red and proton magnetic resonance spectroscopy.
The amino-ended products from both reactions (with terminal butoxy or methoxy groups from "360" and "2070" respectively) were separately converted into the N-methacrylaloyl derivatives thereof and copolymerised with methacrylic acid under the conditions described in Example 11 of EP 0.182,523A.
Hydroxyapatite discs were pre-equilibrated in double distilled water for 1 hour. The discs were removed from the water, blotted dry and kept at room temperature for about 30 minutes. A UV reflectance scan 24 thereof was carried out. The Optical Density at 266 nm was typically about 0.9. Any disc which had an O.D. which was significantly different from this number was rejected.
The acceptable discs were immersed in 1% w/w (l.-l/IMS: water) solution of polymer for 5 minutes. The discs were removed from the polymer solution; were washed by dipping and shaking 5 times in a container of flowing water; were blotted dry; left for 30 minutes and then scanned.
Each of the polymer-coated discs was immersed in aqueous (15 ml) chlorhexidine solution (0.02% w/v) for 1 hour. They were washed as described above, allowed to stand for 30 minutes and then scanned. They were then placed in a flow-through (250 ml/min) washing tank (1200 ml) for 1 hour; blotted dry; allowed to stand for 30 minutes and scanned.
TABLE 4 10 15 20 Example Number Polymer Applied Chlorhexidine Concentration % Difference in Optical Density at 266 nm over blank H A disc % Chlorohexidine retained after washing for 1 hour 17 hours CT12 73 0.02 0.01 nd nd CT13 B12 0.02 0.02 nd nd 10 62 0.02 0.12 80 49 11 86 0.02 0.15 93 58 12 93W 0.02 0.20 79 47 13 66 0.02 0.12 82 39 14 B9 0.02 0.22 82 50 15 58 0. 02 0.14 86 68 16 B3 0.02 0.22 82 45 17 BIO 0.02 0.19 77 54 18 B18 0.02 0. 30 85 57 19 B17 0.02 0.25 77 66 20 Mil 0.02 0.23 b b CT14 PMMA 0.02 0.02 nd nd CT15 None 0.02 0.01 nd nd CT16 None 0.2 0.06 nd nd CT17 None 2 0.18 23 nd PMMA: Polymethacrylic acid. n.d.: Not detected, i.e. below detection limit. b: Not determined.
The meanings ascribed to the polymers listed in Table 4 are shown in Table 5. 26 TABLE 5 Polymer A Backbone Nature (Source) B Side Chain Mol Wt Molar Ratios A: B CHRxCHRa 0: CO,H groups 73 Basic (DMAEM) PEG 350 3:1 B12 Amphoteric PEG 350 1.9:1.1:1 (MAA:DMAEM) 62 Acidic (MAA) PEG 150 3:1 1:1 86 Acidic (MAA) PEG 350 3.5:1 2.3:1 93W Acidic (MAA) PEG 350 6:1 1.3:1 66 Acidic (MAA) PEG 1000 3:1 7.7:1 B9 Acidic (MAA) PEG 1000 25:1 0.9:1 58 Acidic (MAA) PEG 2000 10:1 4.5:1 B3 Acidic (MAA) Jeff 360 6:1 1.1:1 BIO Acidic (MAA) Allyl- PEG 350 6:1 1.3:1 B18 Acidic (MAA) Jeff2070 34:1 1.2:1 B17 Acidic (MAA) PPG 1000 17:1 1:1 Mil Acidic (MAA) PEG 350 5:1 0.9:1 DMAEM:N N-dimethyl-2-aminoethyl methacrylate.
MAA: Methacrylic acid.
MA: Maleic acid; PEG: Polyethylene glycol.
PPG: Polypropylene glycol; Jeff 360 : n-C4H9(OCH,CH,)4OCH,CH(CH,)OCH,CH(CH,)NH,; Jeff 2070: CHj0CH2CH,0(CH,CH0)nCH,CH(CH,)NH2 27 wherein n is such that "2070" has an MW of about 2000 and R = H or CHS in a ratio of about 7:3; Allyl-PEG 350: Ethoxylated allyl alcohol; Except for B10, the methacrylate or methacrylamido 5 derivatives of the indicated side chains were present as general structure B; B10: contains terminal hydroxy groups.
The aforesaid UV scanning was effected using a Unican SP1750 Ultraviolet Spectrophotometer. •jo The "difference in Optical Density" results shown in Table 4 were determined therefrom.
From Tables 4 and 5, it can be seen that the acidic polymers significantly increased the amount of chlorhexidine absorbed. Many of the hydroxyapatite 15 surfaces coated with an acidic polymer absorbed more chlorhexidine from a 0.02% w/v solution than did the neat hydroxyapatite surface from a 2% w/v solution of chlorhexidine, i.e. a greater than a 100-fold improvement was observed. The basic (Polymer 73) and 20 amphoteric (Polymer B12) polymers gave no improvement in the amount of chlorhexidine adsorbed. Similarly, polymethacrylic acid yielded no increase in chlorhexidine adsorbed, indicating that it was the PEG (or PPG) chains, and not the carboxyl groups, that were responsible for 25 the observed effect.
The results of the washing experiments showed that after 1 hour about 23% of the initially adsorbed chlorhexidine was still adsorbed on bare hydroxyapatite discs, whereas the amount for polymer treated discs was 3q approximately 80%. After an overnight wash, the amount of adsorbed chlorhexidine, if any, remaining on the neat HAP discs was below the detection limit; and approximately 50-60% of the amount of chlorhexidine 28 originally adsorbed on polymer-treated discs remained adsorbed. Thus, polymer-treated discs adsorbed more chlorhexidine than bare discs, and it was also less easily washed off the surface thereof. 5 EXAMPLES 21-29 These Examples, in combination with Examples 10-20 and 6-9, reveal an increase in anti-bacterial properties (at a certain chlorhexidine concentration) without the expected increase in staining. 10 General Procedure Hydroxyapatite discs were pre-equilibrated in double- distilled water for 1 hour. The pre-equilibrated discs were immersed in 1% w/v aqueous or IMS:water (1:1) solution of polymer for 5 minutes. They were removed 15 from the polymer solution and washed by dipping and shaking 5 times in a container of flowing water. The washed discs were then immersed in 15 ml of an aqueous chlorhexidine solution (of a concentration shown in Table 6) for 5 minutes. The discs were removed from the 20 chlorhexidine solution and immersed in 15 ml of a tea solution for 1 hour at room temperature. The discs were taken out of the tea solution and washed as described above. The steps of immersion in chlorhexidine and tea solution and washing were repeated 3 times, using fresh 25 chlorhexidine and tea solutions each time. After these three cycles the discs were immersed in tea solution overnight; they were then washed as described above, allowed to dry for 1 hour at room temperature and the amount of stain produced thereon was assessed. 30 The tea solution was prepared by adding 500 ml of boiling water to 2 tea bags. The tea bags were removed after 5 minutes, and the tea allowed to cool to room temperature. The tea was filtered using standard filter paper, and stored at 4°C prior to use. 29 The stained discs prepared in the General Procedure were scanned using UV/visible reflectance spectrophotometry as described in Examples 10-20 and compared with tea blanks (i.e. no.chlorhexidine adsorbed). Figure 1 shows typical UV- traces which were obtained. In Figure 1, a = bare hydroxyapatite disc; b = tea blank; and c,d,e, = tea/chlorhexidine treatments at 0.002%, 0.02% and 0.2% concentrations of chlorhexidine respectively.
The polymers listed in Table 6 (the chemical composition of which are given in Table 5) were evaluated for their effect on the stain formation of chlorhexidine in the presence of tea. The polymers were separately adsorbed from 1% w/v IMS/water (1:1) solutions. 0.2%, 0.2% and 0.002% w/v aqueous solutions of chlorhexidine were used. The discs were scanned using UV/visible reflectance spectrophotometry and the OD's at 266, 410 and 510 nm were measured. The OD's of tea blanks were also measured at these wavelengths, and these values were subtracted from discs treated with chlorhexidine or polymer/ chlorhexidine combinations. Table 6 gives the results at 510 nm. They are expressed as ratios relative to the stain produced by a tea blank = 1.0. Similar results were obtained at 266 nm and 410 nm. In CT 18, the polymer was omitted, i.e. chlorhexidine per se was used. 30 TABLE 6 Comparative Stain Development compared with "Natural" build-up from exposure to tea solutions. 5 Example No Polymer o.d. Ratio (compared with natural tea stain) at 510 nm at applied Chlorhexidine Concentrations of 0.2% 0.02% 0.002% CT18 - 4.57 2.76 1.67 10 21 73 4.48 3.01 1.0 22 62 4.98 2.65 1.0 23 86 4.48 3.26 1.0 24 93W 4.98 2.79 1.0 25 B9 4.75 3.09 <1.0 15 26 B3 4.39 3.34 1.0 27 B10 4.76 3.34 <1.0 28 B18 4.20 3.12 <1.0 29 B17 5.03 2.95 <1.0 From Table 6 it can be seen that at the two higher 20 chlorhexidine concentrations (i.e. 0.2 and 0.02%) the presence or nature of the polymer had no substantial effect on the amount of stain produced on treatment of HAP discs. At the lowest concentration (i.e. 0.002%) of applied chlorhexidine. the majority of Examples show a 25 significant reduction in stain equal to or less than the minimal levels associated with exposure of HAP discs to the tea solutions. However, it will be appreciated from the results in Examples 10-20 and 6-9, that, for about the same stain as the control, the polymers had more 31 chlorhexidine absorbed thereon and exhibited an increased antibacterial effect.
EXAMPLES 30-31 These Examples illustrate the increase in the quantity of chlorhexidine adsorbed onto a hydroxyapatite disc treated with a mixture of chlorhexidine and Polymer 93W compared to treatment of the HAP disc with a chlorhexidine solution per se.
An IMS solution (2% w/v) of Polymer 93W was mixed with an appropriate (0.04% w/v) solution of chlorhexidine in water, at a solution ratio of 1:1 by volume. Hydroxyapatite discs were allowed to stand in the mixture for 1 hour and were then washed five times with water. The amount of chlorhexidine absorbed on the discs was determined by UV reflectance spectrophotometry as described in Examples 10-20 (the Optical Density was measured at 266 nanometers).
In Comparative Tests 20 and 21, the discs were treated for 1 hour with 0.2 and 0.02 % solutions respectively of chlorohexidine in a 1:1 by volume mixture of industrial methylated spirit and water.
The results are shown in Table 7. From Table 7 it can be seen that treatment of a HAP with the Polymer 93W/chlorhexidine mixture results in more chlorhexidine being absorbed than from chlorhexidine solution per se. 32 TABLE 7 Example State of Concentration Increase in No addition of Optical of chlorhexidine Density at composition % w/v 266 nm 30 Mixture 0.2 0.44 31 Mixture 0.02 0.12 CT19 Neat chlorhexidine solution 0.2 0.0 CT20 Neat chlorhexidine solution 0.02 0.0 EXAMPLES 32-33 These Examples illustrate the increased "kill" of a Polymer 93W/chlorhexidine mixture compared with that observed with neat chlorhexidine solution.
The discs prepared in Examples 30-31 were washed overnight in water and subjected to an S.mutans agar overlay experiment. They were placed in a petri-dish and covered with BHI agar (25 mis). S mutans (100 pi), grown in a fermenter (as described above) and diluted x 100 in Ringers salt solution, was pipetted onto the agar and evenly spread. The bacteria were grown overnight at 37°C; "lawns" of bacteria and "clear zones" free of bacteria were noted and measured. The results are shown in Table 8. The clear zones, i.e. zones where growth did not occur, are shown as a percentage of the area of the disc. 33 TABLE 8 Example Disc Concentration % Area of No prepared of disc where in chlorhexidine growth did Example % w/v not occur No 32 30 0.2 225 33 31 0.02 64 CT21 CT19 0.2 3 CT22 CT20 0.02 0 It will be appreciated that where "% Area of disc where growth did not occur" is more than 100, this indicates that inhibition spread into the agar layer beyond the perimeter of the disc.
From Table 8, it can be seen that the mixture has an increased antibacterial activity compared with chlorhexidine per se.
EXAMPLES 34-65 These Examples show that the combination of an anti-adhesive compound. Polymer 93W, and chlorhexidine reduce the amount of staining, compared with chlorhexidine per se, generated on a variety of surfaces found in the oral environment. The surfaces comprised tooth, composite restorative materials, e.g. Occlusin and Opalux, and a methacrylate-based resin conventionally used in the preparation of dental 34 prosthetic devices (hereinafter referred to for convenience as "PR").
SPECIMENS Residual flesh was removed with a scalpel from freshly attracted teeth, the teeth were then tumbled for 20 minutes in 50% sodium hypochlorite solutions and washed superficially with distilled water.
These and teeth containing restorative material were sonicated in alcohol for 10 minutes and then dried.
Samples of OR (25 mm x 10 mm x 3 mm) and discs of the aforementioned composite restoratives were washed in alcohol and dried.
SOLUTIONS a 1% and 0.5% solutions of Polymer 93W (lgm) in a mixture of industrial methylated spirit (50 ml) and water (50 ml). b Solutions (0.2%, 0.02%, and 0.002%) of chlorhexidine in water. c Appropriate mixtures of Polymer 93W and chlorhexidine were obtained by mixing equal volumes of solutions from a and b to afford the concentrations shown in the folowing Tables. d Human saliva was obtained by talcing specimens (20 mis) from each of 6 volunteers, centrifuging for 20 minutes at 2,5000 rpm and pooling them. e Tea solution was prepared by boiling a sample (8g) of a commercial brand of tea in distilled water (80 ml) for 2 minutes, cooling the product to room temperature and filtering off the residual tea leaves. Evaluation Each surface was treated for 10 minutes with a sample of the saliva. Excess saliva was washed off.
In Examples 34-49, the surface was subjected to a first treatment for 10 minutes, superficially washed with distilled water, subjected to the secono treatment for 10 minutes, rinsed and then immersed in the tea 35 solution for 1 hour; the procedure was repeated, the sample was left in the tea solution overnight and the whole procedure repeated every day for 5 days.
In examples 50-65 the above 5 day procedure was 5 repeated except that the first treatment was for 5 minutes and the second treatment was omitted, the samples were treated with appropriate mixtures of Polymer 93W and chlorhexidine.
The staining of the surfaces was compared visually 10 with the same surface treated only with water and scored on the following scale.
Scale 0 : No stain (ie Water-control taken as 0, although there was slight discolouration); 15 1 : Slight stain; 2 ; Moderate stain; 3 : Heavy stain; and 4 : Very heavy stain.
In Tables 9, 10 and 17 20 OC = Occlusin OP = Opalux T = Tooth PR = Prosthetic resin A =0.5% Polymer 93W 25 AA = 1% Polymer 93W B = Water X =0.1% Chlorohexidine XX = 0.2 Y = 0.01 30 YY = 0.02 Z = 0.001 ZZ = 0.002 W 0.0001 36 TABLE 9 Example Surface Treatments Score No First or Second Single (10 mins) (10 mins) CT23 OC B 0 CT24 OP B 0 CT25 T B 0 CT26 PR B 0 CT27 OC X 3 CT28 OP X 3 CT29 T X 3 CT30 PR X 3 CT31 OC AA 0 CT32 OP AA 0 CT33 T AA 0 CT34 PR AA 0 34 OC AA XX 3 35 f • I 1 YY 1 36 • 1 1 t ZZ 0 CT35 1 1 B XX 3 CT36 • • 1 1 YY 2 CT37 1 1 • • ZZ 1 37 OP AA XX 4 38 t 1 1 • YY 2 39 1 • f 1 ZZ 0 CT38 1 • B XX 3 CT39 t 1 » YY 2 3? TABLE 9 - Cont Example Surface Treatments Score No First or Second Single (10 mins) (10 mins) CT40 OP B ZZ 1 40 T AA XX 4 41 « I • I YY 2 42 t • l I ZZ 0 CT41 I » B XX 3 CT42 f i 1 I YY 2 CT43 1 I I 1 ZZ 1 43 PR AA XX 4 44 1 1 1 • YY 2 45 1 1 1 t ZZ 0 CT44 1 « B XX 3 CT45 • I • • YY 2 CT46 • • 1 • ZZ 1 46 OC XX AA 0 47 OP f t f t 0 48 T • 1 t 1 0 49 PR 1 t 1 • 0 38 TABLE 10 Example Surface Treatment Score No (mixture for 5 mins) CT47 OC B 0 CT48 OC X 4 CT49 OC Y 3 CT 50 OC Z 1 CT51 OC W 1 CT52 OC A 0 50 OC A+Y 2 51 OC A+Y 0 52 OC A+Z 0 53 OC A+W 0 CT53 OP B 0 CT54 OP X 4 CT55 OP Y 3 CT56 OP Z 1 CT57 OP W 1 CT58 OP A 0 54 OP A+X 4 55 OP A+Y 3 56 OP A+Z 1 57 OP A+W 1 39 TABLE 11 1 Example Surface Treatment Score No (mixture for 5 mins) CT59 T B 0 CT60 T X 4 CT61 T Y 3 CT62 T Z 1 CT63 T W 1 CT64 T A 0 58 T A+X 2 59 T A+Y 0 60 T A+Z 0 61 T A+W 0 CT65 PR B 0 CT66 PR X 4 CT67 PR Y 2 CT68 PR Z 1 CT69 PR W 1 CT70 PR A 0 62 PR X 2 63 PR Y 0 64 PR Z 0 65 PR A+W 0 From Table 9, it can be seen that at low 25 concentration (eg 0.002%) of chlorhexidine staining of dental restorative, teeth or prosthetic resin is reduced if the surface thereof is first treated with a certain polymer. It can be seen further (Examples 46-49) that where the surfaces are treated with a 40 chlorhexidine solution and then with Polymer 93W the staining is reduced co control levels.
Table 10 reveals the results obtained on treating Occlusin and Opalux surfaces with mixtures of chlorhexidine and Folymer 93W. There is a significant reduction in the staining of Occlusin. to control levels at chlorhexidine concentrations of 0.01% and less; a similar trend is apparent with Opalux.
Table 11 reveals the results obtained on treating tooth surfaces and a prosthetic resin with a mixture of chlorhexidine and Polymer 93W. The trend in the reduction in staining is similar to that observed with Occlusin and Opalux.
Where a tooth with an Occiusin implant was subjected to the above evaluation, the tooth and implant were slightly stained to the same extent such that the outline of the implant was further decreased. 41
Claims (16)
1. An oral hygiene composition which comprises (i) an effective amount of at least one cationic anti-bacterial agent; and (ii) an effective amount of at least one polymer which bears pendant polyalkylene oxide side-chains.
2. An oral hygiene composition as claimed in Claim 1 wherein the >cationic anti-bacterial agent is a polybiguanide or a salt thereof.
3. An oral hygiene composition as claimed in Claim 2 wherein the polybiguanide is a bis-biguanide.
4. An oral hygience composition as claimed in Claim 3 wherein the bis-biguanide is chlorhexidine.
5. An oral hygiene composition as claimed in Claim 1 wherein the least one polymer comprises one or more repeating units of general Structure A. r (COjH) p*s^;and one or more repeating units of general structure B;wherein X, which in the repeating units of structure A may be the same or different, and Y, which in the repeating units of structure B may be the same or different, are hydrocarbyl. or substituted hydrocarbyl residues, providing a backbone for the polymer;;42;Z is-CHR1-CHR2-or-(CH,)m*; wherein, where Z is -CHR1-CHR3 - R1, which in the same repeating unit of structure B (when n or q is 2 or more) or in different repeating units of structure B may be ::he same or different, is hydrogen or a hydrocarbyl group; and Rs. which in the same repeating unit of structure B (when n or q is 2 or more) or in. different repeating units of structure B may be the same or different, is, hydrogen or a hydrocarbyl group; except that R1 and RJ in a single unit-CHR^CHR'-O- cannon both be hydrocarbyl; R3 which in the same repealing unit of structure B (when q is 2 or more) or in different repeating units of structure B may be the same or different, is hydrogen or a hydrocarbyl group or an acyl group derived from an alkanoic acid having up to five carbon atoms; m, where present, is a number of from 2 to 10; n is a number of from 1 to 60; p is a number of from 1 to 4; and q is a number of from 1 to 4; each (COjH) group is joined via an intermediary or intermediaries L to the hydrocarbyl residue X, and in cases where p is 2 to 4 may be joined by L to the same or different carbon atoms of X; L may be the same or different in the repeating units of structure A and is selected from one or more direct links and one or more groups of atoms each group providing a chain of one or more atoms for linking a (COjH) group with X, except that more than two (COjH) groups cannot be directly linked to the same carbon atom in X; each (ZOJ^R'Jq group is joined via an intermediary or intermediaries M to the hydrocarbyl residue Y, and.in cases where q is 2 to 4 may be joined by M to the same or different carbon atoms of Y; M may be the same or different in the repeat units of structure B and is selected from one or more direct links and one or more groups of atoms each group providing a chain of one or more atoms for linking a (Z0)n group with Y, except that more than two (Z0)n groups cannot be directly linked to the same carbon atom in Y; the ratio of the number of -COaH groups to the number of (ZO) groups, particularly where Z is -CH2CHa-, is within the range of 1:20 to 20:1.
6. An oral hygiene composition as claimed in claim 5 wherein,where Z is -CHR1-CHR2-, both R1 and R2 are hydrogen.
7. An oral hygiene composition as claimed in claim 5 where RJ is methyl.
8. An oral hygiene composition as claimed in claim 5 wherein, in structure A, L is a direct link, -CHj-, -CH2-CH2-, -CHj-CH =, -NH-C0-, - CONHCH(CH j)- or -CONHCH(OH)-.
9. An oral hygiene composition as claimed in Claim 5 wherein, in Structure A, p is 1 or 2.
10. An oral hygiene composition as claimed in Claim 5 wherein, in structure B, M is -COO-or CONH-.
11. An oral hygiene composition as claimed in Claim 5 wherein, in structure B, q is 1 or 2.
12. An oral hygiene composition as claimed in Claim 5 wherein A or B represents the repeat unit derivable by 41 the addition-polymerisation of a polymerisable olefinically unsaturated carboxylic acid or an ester or amide derivative thereof respectively.
13. An oral hygiene composition as claimed in Claim 12 wherein the polymerisable olefinically unsaturated carboxylic acid is acrylic acid or methacrylic acid.
14. An oral hygiene composition as claimed in Claim 1 comprising a pharmaceutically acceptable vehicle which is water, ethanol, a humectant, gelling agent, gel stabiliser, sweetener, preservative, surfactant or an approved colour or flavour.
15. An oral hygiene composition as claimed in Claim 1 the form of mouthwash, rinse, irrigating solution, gel dentifrice, denture cleaner, coated dental floss, coated or impregnated tooth-brush bristle, inter-dental stimulator or coating, chewing gum, lozenge, breath freshener, foam or spray.
16. An oral hygiene composition according to Claim 1, substantially as hereinbefore described. f. r. kelly & co., agents for the applicants.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888801025A GB8801025D0 (en) | 1988-01-18 | 1988-01-18 | Oral hygiene composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE883861L true IE883861L (en) | 1989-07-18 |
| IE61979B1 IE61979B1 (en) | 1994-12-14 |
Family
ID=10630121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE386188A IE61979B1 (en) | 1988-01-18 | 1988-12-22 | Oral hygiene composition |
Country Status (23)
| Country | Link |
|---|---|
| JP (1) | JPH01242519A (en) |
| AT (1) | AT393621B (en) |
| AU (1) | AU617144B2 (en) |
| BE (1) | BE1002699A5 (en) |
| CA (1) | CA1335352C (en) |
| CH (1) | CH678598A5 (en) |
| DE (1) | DE3900896A1 (en) |
| DK (1) | DK3789A (en) |
| ES (1) | ES2009690A6 (en) |
| FI (1) | FI93691C (en) |
| FR (1) | FR2625901B1 (en) |
| GB (2) | GB8801025D0 (en) |
| GR (1) | GR1000273B (en) |
| HU (1) | HUT52397A (en) |
| IE (1) | IE61979B1 (en) |
| IT (1) | IT1227849B (en) |
| LU (1) | LU87430A1 (en) |
| NL (1) | NL8900076A (en) |
| NO (1) | NO174914C (en) |
| NZ (1) | NZ227596A (en) |
| PT (1) | PT89466B (en) |
| SE (1) | SE8900156L (en) |
| ZA (1) | ZA8961B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2608131B2 (en) * | 1989-03-14 | 1997-05-07 | サンスター株式会社 | toothbrush |
| US5633083A (en) * | 1989-03-14 | 1997-05-27 | Sunstar Kabushiki | Toothbrush |
| US5462728A (en) * | 1994-04-05 | 1995-10-31 | Blank; Izhak | Pharmaceutical compositions |
| AU2002322916C1 (en) | 2002-08-20 | 2008-04-17 | Alda Pharmaceuticals Corp. | A wide spectrum disinfectant |
| EP1624755A1 (en) | 2003-05-15 | 2006-02-15 | Arch UK Biocides Limited | Composition comprising an acidic copolymer and an antimicrobial agent and use thereof |
| DE602004028015D1 (en) * | 2003-05-15 | 2010-08-19 | Arch Uk Biocides Ltd | ANTIMICROBIAL COMPOSITION CONTAINING A POLYMERIC BIGUANIDE AND A COPOLYMER AND THEIR USE |
| WO2004100663A1 (en) * | 2003-05-15 | 2004-11-25 | Arch Uk Biocides Limited | Antimicrobial compopsition comprising a polymeric biguanide and a copolymer and their use thereof |
| US7217759B2 (en) | 2003-05-20 | 2007-05-15 | Arch Uk Biocides Limited | Composition and use |
| US8603453B2 (en) | 2003-05-20 | 2013-12-10 | Arch Uk Biocides Limited | Antimicrobial polymeric biguanide and acidic co-polymer composition and method of use |
| US7226968B2 (en) | 2003-05-20 | 2007-06-05 | Arch Uk Biocides Limited | Composition and use |
| GB0808557D0 (en) * | 2008-05-13 | 2008-06-18 | 3M Innovative Properties Co | Sampling devices and methods of use |
| TW201031430A (en) * | 2008-11-17 | 2010-09-01 | Glaxosmithkline Llc | Dental appliance cleanser |
| DE102012007212A1 (en) | 2012-04-11 | 2013-10-17 | Merz Pharma Gmbh & Co. Kgaa | Preparation for topical application to mucous membranes with polyhexanide as active ingredient |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB825577A (en) * | 1957-01-22 | 1959-12-16 | Internat Chemical Company Ltd | Improvements in or relating to dentifrices |
| US3976765A (en) * | 1973-11-01 | 1976-08-24 | Colgate-Palmolive Company | Antibacterial oral preparations |
| LU84833A1 (en) * | 1983-05-31 | 1985-03-21 | Oreal | CLEANING PRODUCT FOR TEETH AND MOUTH CARE CONTAINING POLY NON-IONIC SURFACTANT (HYDROXYPROPYL ETHER) |
| US4624849A (en) * | 1984-11-02 | 1986-11-25 | The Procter & Gamble Company | Antimicrobial lozenges |
| GB8428523D0 (en) * | 1984-11-12 | 1984-12-19 | Ici Plc | Oral hygiene composition |
| US5100650A (en) * | 1987-06-30 | 1992-03-31 | Warner-Lambert Company | Anti-bacterial oral composition containing bis-biguanido hexanes |
-
1988
- 1988-01-18 GB GB888801025A patent/GB8801025D0/en active Pending
- 1988-12-22 IE IE386188A patent/IE61979B1/en not_active IP Right Cessation
- 1988-12-22 GB GB8829926A patent/GB2213721B/en not_active Expired - Lifetime
- 1988-12-29 ES ES8804013A patent/ES2009690A6/en not_active Expired
-
1989
- 1989-01-04 ZA ZA8961A patent/ZA8961B/en unknown
- 1989-01-05 DK DK003789A patent/DK3789A/en not_active Application Discontinuation
- 1989-01-11 NZ NZ227596A patent/NZ227596A/en unknown
- 1989-01-12 NL NL8900076A patent/NL8900076A/en not_active Application Discontinuation
- 1989-01-12 IT IT8919074A patent/IT1227849B/en active
- 1989-01-13 DE DE3900896A patent/DE3900896A1/en not_active Withdrawn
- 1989-01-16 AU AU28522/89A patent/AU617144B2/en not_active Ceased
- 1989-01-16 NO NO890180A patent/NO174914C/en unknown
- 1989-01-16 HU HU89137A patent/HUT52397A/en unknown
- 1989-01-17 PT PT89466A patent/PT89466B/en active IP Right Grant
- 1989-01-17 GR GR890100030A patent/GR1000273B/en unknown
- 1989-01-17 FI FI890237A patent/FI93691C/en not_active IP Right Cessation
- 1989-01-17 SE SE8900156A patent/SE8900156L/en not_active Application Discontinuation
- 1989-01-17 JP JP1006073A patent/JPH01242519A/en active Pending
- 1989-01-18 CA CA000588582A patent/CA1335352C/en not_active Expired - Fee Related
- 1989-01-18 FR FR8900562A patent/FR2625901B1/en not_active Expired - Fee Related
- 1989-01-18 AT AT0009089A patent/AT393621B/en not_active IP Right Cessation
- 1989-01-18 BE BE8900052A patent/BE1002699A5/en not_active IP Right Cessation
- 1989-01-18 CH CH151/89A patent/CH678598A5/de not_active IP Right Cessation
- 1989-01-18 LU LU87430A patent/LU87430A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sano et al. | Effect of chitosan rinsing on reduction of dental plaque formation | |
| AU2016362307B2 (en) | Oral care compositions | |
| CA1335352C (en) | Oral hygiene composition | |
| US20050048005A1 (en) | Antimicrobial compositions for dental applications | |
| JPH04257511A (en) | Antibacterial oral composition free from pollution | |
| EP0627908B1 (en) | Compositions | |
| JPS6216923B2 (en) | ||
| CN114502136B (en) | Oral care spray composition comprising hexametaphosphate | |
| EP0966257B1 (en) | Barrier to plaque formation | |
| CN115873233A (en) | Multifunctional polypeptide polymer and preparation method and application thereof | |
| EP0792141B1 (en) | Oral treatment | |
| KR20120058713A (en) | Oral composition for preventing gingival ailment | |
| WO2021140437A1 (en) | Anionic alkyl sulphate component for treating caries | |
| MXPA99005192A (en) | Barrier to plaque formation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |